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Abstract
Background/objective Cardiovascular diseases (CVD) are
the leading cause of mortality in European countries. This
study aimed at estimating the 10-year risk of fatal CVD in
Portuguese adults and to assess the prevalence of major
cardiovascular risk factors, according to the SCORE® risk
prediction system.
Subjects and methods A cross-sectional survey was carried
out in 60 community pharmacies (CP) from October 2005
to January 2006 in a sample of CP users (≥40 and
≤65 years). Data were collected by patient interviews using
a structured questionnaire applied by a trained pharmacist.
Results A total of 1,043 individuals were enrolled in the
study (participation rate: 91%). The mean age was
53.7 years (SD: 7.1) with a ratio men/women of 0.68. The
average risk in the sample was 1.94 (minimum 0, maximum
28, SD=2.69). About 20% of the studied adults were at
high risk, of which 39.4% were asymptomatic. CV risk was
significantly higher in the oldest age group and in men (p<
0.05). The prevalence of main CV risk factors was:
hypertension-54.8%; hypercholesterolemia-63.1%, diabetes-
13.4%; smoking-10.4% and obesity–29.0%. About 1/3 of
those asked had family history of premature CVD. Mean
values of biochemical and clinical parameters were: systolic
blood pressure (mmHg): 134.8±19.7; diastolic blood
pressure (mmHg): 81.0±11.4; total cholesterol (mg/dl):
193.8±34.6; body mass index (kg/m2): 28.0±4.5.
Conclusions According to SCORE®, about one-fifth of the
individuals was classified as high risk, and 7.7% was
asymptomatic. CV risk was significantly higher in the
oldest age group (55–65 years old) and in men (p<0.05).
These results show a high prevalence of some risk factors,
particularly hypertension and hypercholesterolemia.
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Introduction
Cardiovascular diseases (CVD) are the main cause of death
in Europe, accounting for over 4.35 million annual deaths:
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CVDs cause nearly half of all deaths in Europe (49%) and
in the European Union (42%) (Petersen et al. 2005;
European Guidelines of CV Prevention 2003). CVDs are
important sources of disability and loss of productivity,
contributing, in large part, to the escalating costs of health
care (European Guidelines of CV Prevention 2003). In
2000 CVD accounted for 22% of all disability adjusted life
years (DALYs) lost in Europe (WHO European Health
Report 2002).
The detection and treatment of major cardiovascular risk
factors, such as hypertension, hypercholesterolemia, diabetes
and smoking, have substantially reduced the incidence of
cardiovascular deaths (Kuulasmaa et al. 2000; Simon et al.
2006).
The scientific evidence shows that simple additive
models cannot explain the interaction among the risk
factors, since there is a kind of synergy among them.
Instead focussing on the impact of a single risk factor on
the CVD development, the concept of global risk assess-
ment has been emphasised in the last decades (Quaglini
et al. 2005).
In the last 50 years, different multifactorial risk models
have been developed, based on prospective cohort studies,
with the aim of producing models for estimating the
probability of developing CVD in the next x years (x being
a pre-defined period), according to each person’s risk
factors (European Guidelines of CV Prevention 2003;
Quaglini et al. 2005). Such methods allow the population
to be stratified into risk groups that enable the optimisation
and the prioritisation of the course of actions to be taken
(Amariles et al. 2004).
Framingham Heart Study, initiated in 1949, was the first
epidemiological study that prospectively collected popula-
tion-based data on the association between risk factors and
the occurrence of fatal and non-fatal coronary and other
cardiovascular events in a systematic and sustained fashion.
The Framingham risk function was then widely used to
predict the 10-year risk of coronary disease in several
populations. However, its accuracy in predicting the 10-year
coronary events in European cohorts was questioned. In
2003, the SCORE (Systematic Coronary Risk Evaluation)
project group developed a new risk function for cardiovas-
cular (CV) fatal occurrences (Conroy et al. 2003). The
SCORE risk prediction system is derived from 12 European
cohort studies and comprises over 200,000 persons, 3 million
person years of observations and over 7,000 fatal cardiovas-
cular events, covering a wide geographic spread of countries
at different levels of cardiovascular risks. SCORE charts,
derived from the results of the study, allow a rapid estimation
of total fatal cardiovascular events over a 10-year period in a
format suited to the constraints of clinical practice and
classify countries in high- or low-risk region (Conroy et al.
2003). The following risk factors are integrated in SCORE
charts: gender, age, smoking, systolic blood pressure,
diabetes and cholesterol (total cholesterol or cholesterol/
HDL ratio) (Conroy et al. 2003).
Published studies with the same objectives and using the
SCORE system for low-risk countries are scarce, and they
are performed in very specific populations (obese hyper-
tensive patients, nurses)(Schindler et al. 2007; Scholte op
Reimer et al. 2006). A literature review was undertaken,
and no published studies using SCORE® system performed
on the Portuguese population were found.
Portugal, as well as the majority of the western European
countries, presents a high prevalence of the major cardio-
vascular risk factors (namely hypertension, hypercholester-
olemia, diabetes and obesity)(De Macedo et al. 2007; Costa
et al. 2003; Santos and Barros 2003). However, according
to the European Guidelines of Cardiovascular Prevention
(2003), Portugal was classified as a low-risk country.
Several studies demonstrate, through ongoing screening
programmes that community pharmacies can be in a good
position to screen people at risk for CVD and to refer them
to their physicians for further evaluation (Mangum et al.
2003; Hourihan at al. 2003, Atthobari et al. 2004; Snella
et al. 2006).
This study aims to estimate the 10-year risk of fatal CVD
using the SCORE® risk chart for low-risk countries and to
assess the prevalence of major CV risk factors in a sample
of Portuguese adults (40–65 years old) selected in the
community pharmacies.
Methods
Study design
A cross sectional survey was carried out on 60 community
pharmacies (CP) from October 2005 to January 2006 in a
representative sample of Portuguese adults (40–65 years old).
In September 2005, a mixed urban/rural national sample
(stratified by Portuguese Health Regions-North, Centre,
Lisbon Region, Alentejo and Algarve) of community
pharmacies was selected for the implementation of this
study (a total of 60 CP, 12 by each Health Region).
Previous condition for the CP participation was the
executive pharmacist attendance of a training session
performed by the Portuguese Foundation of Cardiology.
Each Community pharmacy had to interview 20 patients,
2 eligible individuals per day (the 1st after 11 AM and the
2nd after 4 PM) that were invited to participate in the study.
If the first invititation was refused, the pharmacist should
select the next one.
Data were collected through patient interviews, using a
comprehensive structured questionnaire (socio-demographic,
clinical, behavioural and therapeutic variables) administered
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by a trained pharmacist. In this systematic sample of adults,
biological and physiological parameters were also measured
(total cholesterol, systolic and diastolic blood pressure and
BMI).
Sampling size
The sample size was estimated assuming a prevalence of
high-risk individuals of 15% (based on data of the
Portuguese Foundation of Cardiology-Centre Region), a
sampling error of 5% and a confidence level of 95%. Based
on this estimation, a total of 1,000 individuals have to be
recruited.
The stratification of the sample was based on the
resident population in 2000 (2001 Census, National
Institute of Statistics–Portugal) by each region, and the
urban/rural ratios were also taken into account.
A total of 1,043 individuals (about 200 in each health
region) was included in the study. Those individuals were
selected in 60 CP, each one including a maximum of 20
users in the study (mean of 17.4 valid questionnaires per
pharmacy).
Inclusion criteria
Adult individuals (age ≥40 and ≤65 years) without visible
or noticeable cognitive impairment and with the ability
to understand the Portuguese language were invited to
participate in the study. The age range was restricted to the
groups referred in SCORE® charts (40–65 years old).
Assessment of global cardiovascular risk
and cardiovascular risk factors
The SCORE® risk estimation model for low-risk regions
was applied in order to access the 10-year risk for fatal
CVD of the individuals (Conroy et al. 2003). High risk was
considered when the score was ≥5% (for asymptomatic
individuals). Patients who reported having already had a
cardiovascular event (coronary or cerebrovascular disease)
were also considered to be at high risk, independently of
the score value. The used SCORE® chart comprises age,
sex, smoking, total cholesterol, diabetes and systolic blood
pressure, providing the overall score of each individual.
The SCORE® chart does not directly comprise diabetes as a
variable. The score risk in diabetic patients was multiplied
two-fold in men and four-fold in women, as stated by
Conroy et al. (2003).
We considered as diabetic people those who reported
having the Diabetic Guide (Self-Care Guide for diabetes
control, given by each health centre, to the diagnosed
diabetic patients) and/or those on anti-diabetic medication
(confirmed by pharmacy records).
Blood pressure was measured by the pharmacist (using
automatic blood pressure monitors, clinically validated
and cuff size adjusted to arm circumference), with
participants rested for at least 5 min, the mean of two
measurements, with an interval of at least 3 min, was
registered.
A capillary blood sample to assess concentrations of
total cholesterol was obtained in the pharmacy (using the
ACCUTREND® GC instrument, a point-of-care analyzer
that is a reliable alternative to conventional laboratory
devices).
As indicated by the WHO Guidelines (WHO-Guidelines
for the Management of Hypertension, 1999), individuals
were considered hypertensive if systolic blood pressure was
≥140 mmHg or diastolic blood pressure was ≥90 mmHg
and/or on anti-hypertensive therapy. In diabetic patients,
hypertension was considered if systolic blood pressure was
≥130 mmHg or diastolic blood pressure was ≥80 mmHg
(WHO-Guidelines for the Management of Hypertension,
1999).
The individuals were considered as having hypercholes-
terolemia if the total cholesterol was over 190 mg/ml and/or
were under anti-hypercholesterolemia medication (European
Guidelines of CV Prevention 2003).
The BMI was calculated as weight (kg) divided by
height squared (m2). The World Health Organization
reported the following categories for BMI (expert panel
on the identification, evaluation and treatment of over-
weight in adults, 1998): underweight (<18.5 kg/m2), normal
(18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), obese
(30.0–39.9 kg/m2) and super-obese (≥40 kg/m2).
The studied sample was classified in terms of smoking
status as current smoking, non-smoking (never smoked)
and past-smoking. Current smoking was considered
in individuals reporting smoking until the day of the
interview.
Statistical analysis
Statistical analysis was performed using statistic software
package SPSS® (V15). Statistic significance was assumed
when p<0.05. The routines used were frequency distribution
and bivariate association by cross tabulation using chi-square
and Fisher exact test for categorical variables and t tests for
continuous variables.
Ethics
The questionnaires were anonymous, with no identification
of the responding individuals: only the initials were
recorded in order to avoid duplications. In accordance to
the Helsinki Declaration, freely given informed consent
was obtained from each person.
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Results
Population profile
A total of 1,147 adult pharmacy users were invited to
participate in this study; 104 refused to be enrolled (9.1%).
The studied sample included 1,043 individuals, of which
59.4% (620) were women and 40.6% were men (423), with
a mean age of 53.66 years old (SD=7.08).
Association between CVD risk classification and demo-
graphic, social and health covariates is presented in Table 1.
Global cardiovascular risk assessment
About 20% of the sample was at high risk to die from
cardiovascular disease in the next 10 years (62.1% men)
and 11.8% assumed to have already had a cardiovascular
event. Around 40% (80) of the high-risk population were
asymptomatic (without established coronary heart disease,
peripheral artery disease or cerebrovascular atherosclerotic
disease (European Guidelines of CV Prevention 2003).
The mean score risk in the sample was 1.94 (minimum 0,
maximum 28, SD=2.69).
According to Table 1, variables such as gender, age
group, working status, self evaluation of health status
and number of visits to the physician in the past year
were statistically associated to the cardiovascular risk
classification.
Figure 1 presents SCORE® risk levels of the studied
sample, stratified by gender(%), according to the proposed
classes by the European Society of Cardiology (European
Guidelines of CV Prevention 2003). It shows a clear
difference in the distribution of the global CV risk. The
great majority of the women presented a global CV risk
≤1%.
Figures 2 and 3 show the distribution of the CV risk
levels (grouped in two classes: high risk (≥5%) and low
risk), by gender and age group.
Table 1 Association between CVD risk classification and demographic, social and health covariates
Variable Frequency n (%) Low CVR n (%) High CVR n (%) P
Gender
Women 620 (59.4) 543 (52.1) 77 (7.4) <0.001
Men 423 (40.6) 297 (28.5) 126 (12.1)
Age group
40–54 years old 526 (50.4) 470 (45.1) 56 (5.4) <0.001
55–65 years old 517 (49.6) 370 (35.5) 147 (14.1)
Type of location
Urban 791 (75.8) 634 (60.8) 157 (15.1) 0.648
Rural 252 (24.2) 206 (19.8) 46 (4.4)
Marital status
Married 865 (83.2) 695 (66.9) 170 (16.4) 0.137
Not married 174 (16.8) 142 (13.6) 32 (3.1)
Years at school
<4 89 (8.5) 67 (6.4) 22 (2.1) 0.057
4–11 515 (49.4) 402 (38.6) 113 (10.8)
≥12 438 (42.1) 371 (35.7) 67 (6.4)
Working status
Employed 600 (57.5) 520 (49.9) 80 (7.7) 0.001
Unemployed 45 (4.3) 33 (3.2) 12 (1.2)
Retired 218 (20.9) 136 (13.0) 82 (7.9)
Work at home 180 (17.3) 151 (14.5) 29 (2.8)
Self-evaluation of health status
Very good/good 396 (38.1) 347 (73.7) 49 (4.7) 0.001
Reasonable 539 (51.8) 420 (40.3) 119 (11.4)
Bad/very bad 106 (10.2) 85 (7.0) 34 (3.3)
No. visits to physician the last year
None 121 (11.7) 101 (9.7) 20 (1.9) 0.001
1 – 3 560 (54.1) 471 (45.5) 89 (8.9)
More than 3 355 (34.3) 261 (25.2) 94 (9.1)
Co-morbidities (other than CV)
No 515 (49.4) 424 (40.7) 91 (8.7) 0.149
Yes 528 (50.6) 416 (39.9) 112 (10.7)
364 J Public Health (2008) 16:361–367
As expected, the CV risk was higher in the male gender
as well as in older participants (p<0.05).
Prevalence of major CV risk factors
The prevalence of modifiable/controllable risk factors was:
hypertension 54.8%, hypercholesterolemia 63.1%, diabetes
13.4%, smoking 10.4%, overweight 45.6% and obesity
29%. Table 2 presents the distribution of the major CV risk
factors, by gender.
Hypertension and obesity were significantly more
frequent in women, while diabetes and smoking were
significantly more frequent in men (p<0.05).
The mean values and standard deviation of the clinical
and biochemical parameters in the studied population were:
systolic blood pressure (mmHg): 134.8±19.7; diastolic
blood pressure (mmHg): 81.0±11.4; total cholesterol (mg/dl):
193.8±34.6 and BMI (kg/m2): 28.0±4.5.
Discussion
According to SCORE®, 19.5% of the studied population
was at high risk of dying of CVD in the next 10 years.
Considering the prevalence of high-risk individuals, the
mean age of 53.66 years and the fact that 57.5% reported to
have professional activity, we can anticipate the negative
impact, at the individual and social level, with humanistic
and economic consequences. These results suggest the need
to develop national strategies to improve prevention, detec-
tion and treatment of the main cardiovascular risk factors.
The publications about studies with the same objective
and using the SCORE system carried out in low-risk
countries (Belgium, France, Italy, Luxemburg, Spain,
Switzerland and Portugal) are scarce and performed in very
specific populations. Since there is no published information
using the SCORE® system in Portugal, until now, we could
not compare our results with others performed in the
Portuguese population.
In Spain, some authors reported a prevalence of high risk
in asymptomatic and non-diabetic individuals ranging from
4.1–9.2% (Gonzalez et al. 2006; Buitrago et al. 2007;
Fornasini et al. 2006). In one of the studies, the prevalence
of high-risk individuals raises to 29.2% when diabetic
patients were included (Fornasini et al. 2006).
Since the prevalence of high-risk individuals, considering
just the asymptomatic and non-diabetic individuals, was
5.2% (40/764), our results were similar to those obtained in
Spain, a neighbour country also classified as “low-risk”
according to SCORE®.
As expected, the CV risk was higher in male gender as
well as in older participants: CVDs are strongly related to
age and male gender, but attenuation of the gender factor
occurs in all populations at older age, reason why the
European Guidelines concluded that one should use gender-
specific risk estimation charts, but propose the same
preventive measures in terms of risk management and
lifestyle changes (European Guidelines of CV Prevention
2003).
Our study shows a high frequency of several CV risk
factors, namely hypertension (54.8%), hypercholesterolemia
(63.1) and obesity (29%). The frequencies of these factors
are in line with other Portuguese population-based data for
similar age groups (40 to 65 years old) that presented the
following prevalences: hypertension-54.7% (De Macedo
et al. 2007) (35–64 years old), hypercholesterolemia-
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63.8% (Costa et al. 2003) and obesity-28.8% (Santos and
Barros 2003) (40–69 years old).
Regarding diabetes mellitus, its prevalence observed in
our study (13.4%) was higher than that estimated by WHO
for Portugal (7.4%-20–79 years old) (WHO Regional
publications-European CV Disease Statistics 2005). This
fact can be explained by the included different age groups.
It should be emphasised that, in our study, the majority
of the population presented mean values of total cholesterol
(193.81±34.61 mg/ml) and BMI (28.02±4.53) above the
cut offs stated as recommended in international guidelines.
Despite the fact that the Portuguese population was not
included in the original cohort used by the SCORE®
project group to build the charts and that there is no specific
SCORE® chart for Portugal, the use of SCORE® system
can bring relevant information from the epidemiologic and
preventive viewpoints.
However, it is important to remember that a paramount
aim of the systematic coronary risk evaluation project was
to encourage the development of national guidelines on
prevention of cardiovascular disease, highlighting the
importance of evaluating risk scoring systems against
epidemiological data from the population to be screened
(Getz et al. 2005). In Portugal, this evaluation could be
especially relevant, as the Portuguese population is affected
by the highest mortality rates from cerebrovascular disease
of all the countries in the European Union, being an
exception in Western Europe-162/100,000 per year among
men and 95/100,000 per year among women (Sarti et al.
2000).
Therefore, it is urgent to implement the European
Guidelines on cardiovascular prevention in Portugal using
SCORE® charts to identify the high-risk individuals. This
will allow an intervention in high-risk groups in order to
control and to reduce this major public health problem
among the Portuguese population.
The high participation rate (91%) and the fact that the
results for the frequencies of the major CV risk factors are
in line with Portuguese population-based data (for similar
age groups) seem to indicate that community pharmacy can
be a valuable and feasible alternative to survey the extent to
which populations are affected by chronic conditions,
namely cardiovascular risk.
Our study has some limitations that need to be
considered when interpreting the results. Firstly, we cannot
exclude a selection bias due to the recruitment method,
since community pharmacy users represent a selective
group of the population. Secondly, since this is a multi-
centric study, some variation in the implementation of the
study is difficult to avoid. However, to the extent possible,
Table 2 Distribution of the
major CV risk factors,
by gender
Major cardiovascular risk factors of the study participants Women n (%) Men n (%) Total n (%)
Family history of premature CVD
No 403 (38.7) 299 (28.7) 702 (67.4)
Yes 216 (20.7) 123 (11.8) 339 (32.6)
χ2=3.775; p>0,05
Hypertension
No 306 (29.4) 165 (15.8) 471 (45.2)
Yes 313 (30.0) 258 (24.8) 571 (54.8)
χ2=11.031; p=0.001
Hypercholesterolemia
No 224 (21.5) 160 (15.4) 384 (36.9)
Yes 394 (37.8) 263 (25.3) 657 (63.1)
χ2=0.269; p>0.05
Diabetes mellitus
No 553 (53.1) 349 (33.5) 902 (86.6)
Yes 65 (6.2) 74 (7.1) 139 (13.4)
χ2=10.563; p=0.001
Smoking status
Non smoker 500 (47.9) 141 (13.5) 641 (61.5)
Current-smoker 61 (5.8) 108 (10.4) 169 (16.2)
Past-smoker 59 (5.7) 174 (16.7) 233 (22.3)
χ2=242.329; p<0.001
Obesity
Body mass index <25 180 (17.4) 84 (8.1) 264 (25.5)
Body mass index ≥25 and <30 259 (25.0) 213 (20.6) 472 (45.6)
Body mass index ≥30 and <40 165 (15.9) 121 (11.7) 286 (27.6)
Body mass index ≥40 11 (1.1) 3 (0.3) 14 (1.4)
χ2=14.928; p=0.002
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we standardised procedures and materials across commu-
nity pharmacies (this aspect was specially focussed on in
the training session).
Conclusion
– The prevalence of some risk factors, particularly
hypertension and hypercholesterolemia, was very high
in the studied sample, but similar to the prevalence
found in other Portuguese studies.
– According to SCORE system, about one-fifth of the
individuals was classified as high risk, presenting a risk
of 5% or more to have a fatal cardiovascular event in
the next 10 years.
– Community pharmacy seems to be a valuable and
feasible place to get data, assessing the extent to which
populations are affected by chronic conditions, namely
cardiovascular risk.
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